 |
Previous Article | Next Article 
The Journal of Neuroscience, May 1, 2002, 22(9):3473-3483
Lentiviral-Mediated Delivery of Mutant Huntingtin in the Striatum
of Rats Induces a Selective Neuropathology Modulated by
Polyglutamine Repeat Size, Huntingtin Expression Levels, and Protein
Length
Luis Pereira
de Almeida1, 2,
Christopher A.
Ross3,
Diana
Zala1, 4,
Patrick
Aebischer1, 4, and
Nicole
Déglon1, 4
1 Division of Surgical Research and Gene Therapy
Center, Lausanne University Medical School, 1011 Lausanne, Switzerland,
2 Laboratory of Pharmaceutical Technology, Faculty of
Pharmacy and Center for Neuroscience, University of Coimbra, 3000 Coimbra, Portugal, 3 Division of Neurobiology, Departments
of Psychiatry and Neuroscience, Johns Hopkins University School of
Medicine, Baltimore, Maryland 21205-2196, and 4 Swiss
Federal Institute of Technology Lausanne, 1015 Lausanne,
Switzerland
A new strategy based on lentiviral-mediated delivery of mutant
huntingtin (htt) was used to create a genetic model of Huntington's disease (HD) in rats and to assess the relative contribution of polyglutamine (CAG) repeat size, htt expression levels, and protein length on the onset and specificity of the pathology. Lentiviral vectors coding for the first 171, 853, and 1520 amino acids of wild-type (19 CAG) or mutant htt (44, 66, and 82 CAG) driven by either
the phosphoglycerate kinase 1 (PGK) or the cytomegalovirus (CMV)
promoters were injected in rat striatum. A progressive pathology characterized by sequential appearance of ubiquitinated htt aggregates, loss of dopamine- and cAMP-regulated phosphoprotein of 32 kDa staining,
and cell death was observed over 6 months with mutant htt. Earlier
onset and more severe pathology occurred with shorter fragments, longer
CAG repeats, and higher expression levels. Interestingly, the
aggregates were predominantly located in the nucleus of
PGK-htt171-injected rats, whereas they were present in both the nucleus
and processes of CMV-htt171-injected animals expressing lower transgene
levels. Finally, a selective sparing of interneurons was observed in
animals injected with vectors expressing mutant htt. These data
demonstrate that lentiviral-mediated expression of mutant htt provides
a robust in vivo genetic model for selective neural
degeneration that will facilitate future studies on the pathogenesis of
cell death and experimental therapeutics for HD.
Key words:
Huntington's disease; genetic model; huntingtin; lentiviral vector; gene delivery; rat
Copyright © 2002 Society for Neuroscience 0270-6474/02/2293473-11$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
A. L. Southwell, J. Ko, and P. H. Patterson
Intrabody Gene Therapy Ameliorates Motor, Cognitive, and Neuropathological Symptoms in Multiple Mouse Models of Huntington's Disease
J. Neurosci.,
October 28, 2009;
29(43):
13589 - 13602.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. B. Brown, A. I. Bogush, and M. E. Ehrlich
Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse
Hum. Mol. Genet.,
October 15, 2008;
17(20):
3095 - 3104.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Alves, E. Regulier, I. Nascimento-Ferreira, R. Hassig, N. Dufour, A. Koeppen, A. L. Carvalho, S. Simoes, M. C. P. de Lima, E. Brouillet, et al.
Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease
Hum. Mol. Genet.,
July 15, 2008;
17(14):
2071 - 2083.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B.-X. Pan, F. Vautier, W. Ito, V. Y. Bolshakov, and A. Morozov
Enhanced Cortico-Amygdala Efficacy and Suppressed Fear in Absence of Rap1
J. Neurosci.,
February 27, 2008;
28(9):
2089 - 2098.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. DiFiglia, M. Sena-Esteves, K. Chase, E. Sapp, E. Pfister, M. Sass, J. Yoder, P. Reeves, R. K. Pandey, K. G. Rajeev, et al.
Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits
PNAS,
October 23, 2007;
104(43):
17204 - 17209.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Rockabrand, N. Slepko, A. Pantalone, V. N. Nukala, A. Kazantsev, J. L. Marsh, P. G. Sullivan, J. S. Steffan, S. L. Sensi, and L. M. Thompson
The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis
Hum. Mol. Genet.,
January 1, 2007;
16(1):
61 - 77.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Arango, S. Holbert, D. Zala, E. Brouillet, J. Pearson, E. Regulier, A. K. Thakur, P. Aebischer, R. Wetzel, N. Deglon, et al.
CA150 expression delays striatal cell death in overexpression and knock-in conditions for mutant huntingtin neurotoxicity.
J. Neurosci.,
April 26, 2006;
26(17):
4649 - 4659.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Benchoua, Y. Trioulier, D. Zala, M.-C. Gaillard, N. Lefort, N. Dufour, F. Saudou, J.-M. Elalouf, E. Hirsch, P. Hantraye, et al.
Involvement of Mitochondrial Complex II Defects in Neuronal Death Produced by N-Terminus Fragment of Mutated Huntingtin
Mol. Biol. Cell,
April 1, 2006;
17(4):
1652 - 1663.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Pardo, E. Colin, E. Regulier, P. Aebischer, N. Deglon, S. Humbert, and F. Saudou
Inhibition of Calcineurin by FK506 Protects against Polyglutamine-Huntingtin Toxicity through an Increase of Huntingtin Phosphorylation at S421
J. Neurosci.,
February 1, 2006;
26(5):
1635 - 1645.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Regulier, Y. Trottier, V. Perrin, P. Aebischer, and N. Deglon
Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum
Hum. Mol. Genet.,
November 1, 2003;
12(21):
2827 - 2836.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|